Biogen (BIIB) Tops Q2 EPS by 24c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $248.93 -0.03%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
WMK, FACO, SEB, More
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
WMK, FACO, SEB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.
- Total revenue Mid-single digit percentage decline
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Varonis Systems (VRNS) Tops Q3 EPS by 6c
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
